In a large real world study, tirzepatide was associated with a lower incidence of major cardiovascular outcomes vs semaglutide: Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) New onset heart GLP 1 Medications Inspira Health Medication Assisted Treatment for Alcohol Use Disorder: How Does It Work? Oar Health Navigating TMS Coverage: Blue Cross Blue Shield PCOS and Semaglutide Weight Loss Journey Week 1 Update liraglutide 0.6 mg 0.1 mL (18 mg 3 mL) subcutaneous pen injector Kaiser Permanente